Initial study data indicate GEM103 can regulate complement activity in geographic atrophy secondary to dry age-related macular degeneration and has a tolerable safety profile, according to a press ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results